Oxford Instruments FY26 trading update: in line, with a powerful finish
Oxford Instruments has delivered a solid full-year performance for the 12 months to 31 March 2026, in line with market expectations for continuing operations (excluding the exited NanoScience business). The second half did the heavy lifting after a choppy start, with orders and execution both improving as the year progressed.
Two big headlines stand out. First, Group order intake rose about 8% on an organic constant currency (OCC) basis, giving a healthy book-to-bill of roughly 1.07 (orders received divided by revenue billed). Second, Advanced Technologies posted striking order momentum, helped by the compound semiconductor market and traction with volume manufacturing customers.
At a glance: key figures and milestones
| Group order intake growth (OCC) | c. 8% vs prior year |
| Book-to-bill ratio | c. 1.07 |
| H2 revenue trend | Marginally below prior year on a reported basis; slightly positive on an OCC basis |
| Advanced Technologies order growth (OCC) | c. 30% year-on-year; acceleration in H2 |
| Advanced Technologies order book visibility | Materially covers planned FY27 revenue; orders extend into FY28 |
| Share buyback | First £50m tranche completed; £11.7m of second £50m tranche completed by 31 March 2026 |
| Market expectations for FY26 (consensus) | Revenue £420.7m; adjusted operating profit £71.3m; adjusted margin 16.9% |
OCC means stripping out currency swings and focusing on like-for-like performance. Adjusted figures exclude items such as amortisation of acquired intangibles and non-recurring costs.
Advanced Technologies: order surge sets the pace for FY27
Advanced Technologies (AT) is the clear growth engine here. Orders grew about 30% on an OCC basis year-on-year, with momentum accelerating in the second half. Management cites tailwinds in compound semiconductors and increasing traction with volume manufacturing customers, especially large US and European commercial accounts.
Critically, after receiving a significant multi-year order in April 2026, the AT order book now materially covers planned FY27 revenue, with orders reaching into FY28. That is excellent revenue visibility in a market that can be cyclical. It reduces forecast risk heading into the new financial year and gives operations a clearer runway to plan capacity and delivery.
My take: this is the heart of the bull case for the shares right now. Strong orders from blue-chip customers plus multi-year cover signals both market health and competitive position. The caveat is execution – converting that order book to revenue on time and at the intended margins will be watched closely.
Imaging & Analysis: recovering after tariff disruption
Imaging & Analysis (I&A) had a tariff-disrupted start to the year but saw quarter-on-quarter improvement in order intake. Full-year I&A orders are expected to be in line with last year on a reported basis and marginally up OCC, with a return to growth in H2.
That recovery matters. It tells us the initial headwind was transitory rather than structural, and it underpins the Group’s order book quality going into FY27. However, the division does not have the same step-change momentum as AT. Management’s commentary implies stabilisation and incremental improvement rather than a surge.
Margins and execution: restructuring benefits coming through
Group operating profit margin benefited from cost actions at the Belfast-based imaging business and from higher H2 volumes. While absolute margin figures are not disclosed in the update, the direction of travel is positive, and consensus expects a 16.9% adjusted operating margin for FY26.
Two points to note. First, H2 revenue was marginally below the prior year on a reported basis, but flipped to slightly positive growth on OCC – helpful for margins. Second, the cost restructuring actions appear to be delivering as intended. If the order book converts cleanly, there is scope for further margin support into FY27.
Capital returns: buyback progress signals confidence
Oxford Instruments completed the first £50 million tranche of its share buyback by the end of February. As at 31 March 2026, £11.7 million of the second £50 million tranche had been completed. In straightforward terms, the company is returning meaningful capital to shareholders while reporting strong order momentum – a confident combination.
Buybacks do not guarantee share price performance, but they can enhance earnings per share and signal management’s conviction in future cash generation. The ongoing programme provides a steady technical bid for the shares.
Why this update matters for investors
- Revenue visibility up sharply: AT’s order book materially covers FY27 plans and stretches into FY28, de-risking the near-term outlook.
- Momentum where it counts: 30% OCC order growth in AT and H2 acceleration point to sustained demand in compound semiconductors and volume manufacturing.
- Margin foundation improving: restructuring benefits and a stronger second half support the consensus margin view.
- Cash discipline and returns: a live £100 million buyback programme, with £61.7 million completed by year-end across both tranches, underlines balance sheet strength and confidence.
On the flip side, reported H2 revenue was marginally down year-on-year, and I&A’s recovery, while welcome, is not a breakout. The task now is delivery – converting the enlarged order book into timely, profitable shipments.
What to watch into the prelims on 9 June 2026
- Order conversion and lead times: any commentary on supply chain, manufacturing capacity and phasing of the FY27 AT order book.
- Margins by division: evidence that Belfast cost actions are sustainably embedded and that mix is helping Group margins.
- I&A trajectory: whether the division’s return to growth in H2 continues into the new year after the initial tariff issues.
- Cash and buyback cadence: pace of the second £50 million tranche and any update on capital allocation priorities.
- Currency effects: OCC growth is positive, but reported numbers will still reflect actual exchange rates and hedging.
Josh’s bottom line
This is a reassuring update: full-year results in line with expectations, stronger second half delivery, and standout AT orders that meaningfully de-risk FY27. The combination of a 1.07 book-to-bill, 8% OCC order growth for the Group, and a multi-year AT order win tips the balance positive, in my view.
Risks remain around execution and the pace of recovery in I&A, and reported H2 revenue was still a touch lower year-on-year. But the order book, margin tailwinds, and active buyback provide a solid platform. Eyes now turn to 9 June for the detailed numbers and guidance colour.
